Evidence map›Paper›PMID 29577616›Full record

ArticleJournal of the International AIDS Society2018

Skating on thin ice: stimulant use and sub-optimal adherence to HIV pre-exposure prophylaxis.

J Carlo Hojilla, David Vlahov, David V Glidden, K Rivet Amico, Megha Mehrotra, Robert Hance, Robert M Grant, Adam W Carrico

2 registry-linked trialsAbstract read
In one paragraph

Article in Journal of the International AIDS Society, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 46 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04706624 nacompletednot on this mapstarted 2021, after this paper: background citation

Screen, Treat and Retain Meth-using People With Opioid Use Disorders at Methadone Clinics

TypeinterventionalSponsorHanoi Medical UniversityRan2021 to 2025Enrolled667ConditionsMethamphetamine Abuse, Opioid-use Disorder, HIV SeropositivityArmsContingency management (12 weeks), Contingency management (6 weeks), SMS reminders, Matrix only, Matrix + Contingency management
NCT07281378 nanot yet recruitingnot on this mapstarted 2026, after this paper: background citation

Reducing Co-occurring Substance Use and HIV Risk Among Stimulant-using Men at High Risk for HIV in the United States of America.

TypeinterventionalSponsorUniversity of FloridaRan2026 to 2027Enrolled84ConditionsDrug Use Disorders, PrEP Uptake, PrEP Adherence, HIV Risk BehaviorArmsTailored Positive Affect Intervention, Contingency Management
3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pre-exposure Prophylaxis Adherence Among Men Who Have Sex With Men: A Systematic Review and Meta-analysis.Journal of preventive medicine and public health = Yebang Uihakhoe chi · 2024
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Missed Opportunity or Cause for Concern? Methamphetamine Use Is Associated With Greater Interest in Event-Driven PrEP Among Sexual Minority Men.AIDS education and prevention : official publication of the International Society for AIDS Education · 2024
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

J Carlo HojillaUniversity of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0001-8654-8445
David VlahovYale University, West Haven, CT, USA.
David V GliddenUniversity of California, San Francisco, San Francisco, CA, USA.
K Rivet AmicoUniversity of Michigan, Ann Arbor, MI, USA.
Megha MehrotraUniversity of California, San Francisco, San Francisco, CA, USA.
Robert HanceJ. David Gladstone Institutes, San Francisco, CA, USA.
Robert M GrantUniversity of California, San Francisco, San Francisco, CA, USA.
Adam W CarricoUniversity of Miami, Miami, FL, USA.ORCID 0000-0002-8146-5701

Funding

Chemoprophylaxis for HIV Prevention in Men SupplementU01AI064002 · NIAID · J. DAVID GLADSTONE INSTITUTES · PI GRANT, ROBERT M. · 2005 to 2011
$41.3M
Chemoprophylaxis and HIV Host InteractionsR01AI118575 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRANT, ROBERT M. · 2015 to 2019
$2.9M
PrEP and ART adherence monitoring using dried blood spotsU01AI106499 · NIAID · UNIVERSITY OF COLORADO DENVER · PI ANDERSON, PETER L. · 2013 to 2016
$2.9M
RCT of an integrative intervention for non-treatment-seeking meth usersR01DA033854 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CARRICO, ADAM WAYNE, MOSKOWITZ, JUDITH T. · 2013 to 2017
$2.8M
Comparison of Pharmacologic Markers of Exposure to HIV Pre-Exposure ProphylaxisR03AI122908 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GLIDDEN, DAVID V. · 2016 to 2017
$159k
PrEP disengagement in stimulant and heavy alcohol using men who have sex with men and transgender women.R36DA041906 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HOJILLA, JOSE CARLO GLANG · 2016 to 2017
$108k
NIAID NIH HHS U01 AI064002NIAID NIH HHS U01 AI106499NIDA NIH HHS R01 DA033854NIDA NIH HHS R36 DA041906
6 · The paper itself

Abstract

introductionStimulant and heavy alcohol use are prevalent and associated with elevated risk for HIV seroconversion among men who have sex with men (MSM) and transgender women. In addition, each can pose difficulties for antiretroviral adherence among people living with HIV. Scant research has examined the associations of stimulant and heavy alcohol use with adherence to daily oral pre-exposure prophylaxis (PrEP) among MSM and transgender women. To address this gap in the literature, we evaluated the hypothesis that stimulant use and binge drinking are prospectively associated with sub-optimal PrEP adherence.

methodsWe analysed data from participants in a nested case-cohort in the iPrEx open label extension. Stimulant use (i.e. powder cocaine, crack-cocaine, cocaine paste, methamphetamine, cathinone) and binge drinking (i.e. ≥5 drinks in a single day) in the last 30 days were assessed. Baseline urine was tested for stimulants using immunoassays to reduce misclassification. Sub-optimal adherence was defined as tenofovir drug concentrations in dried blood spots less than 700 fmol per punch, indicative of less than four doses per week. We tested the prospective association of stimulant use and binge drinking with sub-optimal adherence at the 4-week follow-up visit. RESULTS AND DISCUSSION: Data from 330 participants were analysed. The majority of the participants were MSM (89%) with a median age at baseline of 29 years (interquartile range 24 to 39). Approximately 16% (52/330) used stimulants and 22% (72/330) reported binge drinking in the last 30 days. Stimulant users had fivefold greater odds of sub-optimal PrEP adherence compared to non-users in adjusted analysis (adjusted odds ratio [aOR] 5.04; [95% CI 1.35 to 18.78]). Self-reported binge drinking was not significantly associated with sub-optimal adherence after adjusting for stimulant use and baseline confounders (aOR 1.16 [0.49 to 2.73]). Depressive symptoms, being transgender, and number of sex partners were also not significantly associated with sub-optimal PrEP adherence (p > 0.05).

conclusionsStimulant use is a risk factor for sub-optimal PrEP adherence in the month following PrEP initiation. Comprehensive prevention approaches that reduce stimulant use may optimize PrEP adherence. Creating adherence plans that specifically address PrEP dosing in the context of ongoing stimulant use should also be considered.

Indexed as

Homosexuality, MaleMedication AdherenceTransgender PersonsAdultAnti-Retroviral AgentsCentral Nervous System StimulantsFemaleHIV InfectionsHumansMalePre-Exposure ProphylaxisProspective StudiesAnti-Retroviral AgentsCentral Nervous System Stimulantsadherencebinge drinkingdrug usemen who have sex with menpre-exposure prophylaxisstimulant usetransgender persons

Identifiers

PMID29577616
PMCPMC5867332

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.